Tart Cherry Concentrate for Post-Operative Atrial Fibrillation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how tart cherry concentrate might benefit individuals undergoing heart surgery, specifically in preventing post-operative atrial fibrillation (POAF), a common heart rhythm issue after surgery. Researchers are also studying the treatment's effects on inflammation and related outcomes. Participants will consume a specific amount of Montmorency tart cherry juice concentrate daily for three days. Suitable candidates for this trial are those undergoing elective mitral valve repair surgery without any prior heart rhythm issues, such as atrial fibrillation. As a Phase 1, Phase 2 trial, this research aims to understand how the treatment works in people and assess its effectiveness in an initial, smaller group.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using antiarrhythmic agents or corticosteroids (medications that affect the immune system).
Is there any evidence suggesting that Tart Cherry Concentrate is likely to be safe for humans?
Studies have shown that tart cherry concentrate is generally safe for people. One study found that tart cherry juice, containing natural plant compounds called anthocyanins, did not affect heart health in terms of artery stiffness or heart disease risk, indicating it is usually well-tolerated by the body.
Research also shows that tart cherries can reduce oxidative stress, where harmful molecules damage cells, and lower inflammation in the hearts of obese rats. Although more studies are needed in humans, these findings suggest tart cherry concentrate might have soothing effects on the heart.
Experts generally consider tart cherry juice and supplements safe because they help reduce inflammation, with no known serious side effects. However, as with any supplement, individuals should be aware of any personal allergies or interactions with other medications.
In summary, current evidence suggests tart cherry concentrate is safe and well-tolerated, with potential benefits for heart health.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for post-operative atrial fibrillation, which often include medications like beta-blockers and amiodarone, tart cherry concentrate is a natural approach that leverages the properties of Montmorency tart cherries. Researchers are excited about this treatment because tart cherries are rich in antioxidants and anti-inflammatory compounds, which may help reduce inflammation and oxidative stress, factors that can contribute to atrial fibrillation. Another appealing feature is its rapid potential for effectiveness, as the concentrate is consumed in small, daily servings over just three days, offering a quick and convenient alternative to traditional medications.
What evidence suggests that Tart Cherry Concentrate might be an effective treatment for post-operative atrial fibrillation?
Research has shown that tart cherry concentrate might help reduce inflammation and stress-related damage in the body, benefiting heart health. Animal studies found that tart cherries can lower heart inflammation. Drinking tart cherry juice daily has also been linked to slowing the hardening of arteries, crucial for maintaining heart health. Other research suggests that tart cherries aid recovery after intense exercise, indicating broader recovery benefits. Although specific information on tart cherries' effects on post-operative atrial fibrillation (a heart rhythm issue) is limited, these benefits suggest potential advantages for heart health and recovery. Participants in this trial will receive tart cherry concentrate to evaluate its effects on post-operative atrial fibrillation.16789
Who Is on the Research Team?
Steven F Bolling, MD
Principal Investigator
University of Michigan
Are You a Good Fit for This Trial?
This trial is for men and women aged 50-79 who are undergoing elective mitral valve repair surgery but not the Cox MAZE procedure. Candidates should be in normal heart rhythm with no history of atrial fibrillation, no prior heart surgeries, pacemakers, or active smoking. They shouldn't have inflammatory diseases, autoimmune conditions, or be on immunosuppressive drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Tart Cherry Concentrate for three days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tart Cherry Concentrate
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor
Cherry Marketing Institute, Dewitt MI (USA)
Collaborator